FDA and FTC warn Sal Nature/FertilHerb that fertility supplement website claims make it an unapproved drug and misbranded.
What happened
FDA reviewed www.fertilherb.com in March 2021 and found it took orders for “FertilHerb for Women” and made claims that the supplement treats fertility problems, polycystic ovary syndrome (PCOS), irregular menstruation, and miscarriage risk. FDA says those claims make the product a drug intended for disease treatment, and that it is a “new drug” (one needing FDA approval before sale) without approval and misbranded (mislabeled under the law) because it lacks adequate directions for use. FTC reviewed the website in May 2021 and raised concerns that the efficacy claims lack competent and reliable scientific evidence.
What FDA found
Website claims say FertilHerb for Women treats or prevents fertility disorders, PCOS, irregular menstruation, or miscarriage risk, so FDA treats it as a drug.
Section 201(g)(1)(B) of the Act [21 U.S.C. § 321(g)(1)(B)]The product is a new drug because it is not generally recognized as safe and effective for the claimed uses and has no FDA approval.
Sections 201(p), 301(d), and 505(a) of the Act [21 U.S.C. §§ 321(p), 331(d), 355(a)]The product is misbranded because it lacks adequate directions for laypeople to use it safely for its intended disease uses.
Section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]; 21 C.F.R. § 201.5FTC says the advertising claims may not be supported by competent and reliable scientific evidence as required by the FTC Act.
FTC Act, 15 U.S.C. § 41 et seq.
What FDA wants
FDA asks the company to notify FDA in writing within 15 working days of receipt of the letter of the specific steps taken to address the violations, including steps to prevent recurrence and related documents; if corrections cannot be completed in that time, the company must explain the delay and when it will finish.
Who should pay attention
- dietary supplement brands that make fertility or disease-related claims
- marketers and compliance teams reviewing website claims
- companies selling supplements without FDA drug approval
This is a summary. Read the original letter on fda.gov.